Historical Valuation
Pharming Group NV (PHAR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.03 is considered Undervalued compared with the five-year average of -53.58. The fair price of Pharming Group NV (PHAR) is between 33.94 to 39.84 according to relative valuation methord. Compared to the current price of 17.89 USD , Pharming Group NV is Undervalued By 47.3%.
Relative Value
Fair Zone
33.94-39.84
Current Price：17.89
47.3%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Pharming Group NV (PHAR) has a current Price-to-Book (P/B) ratio of 32.53. Compared to its 3-year average P/B ratio of 12.56 , the current P/B ratio is approximately 159.02% higher. Relative to its 5-year average P/B ratio of 8.88, the current P/B ratio is about 266.24% higher. Pharming Group NV (PHAR) has a Forward Free Cash Flow (FCF) yield of approximately 4.49%. Compared to its 3-year average FCF yield of 0.10%, the current FCF yield is approximately 4228.24% lower. Relative to its 5-year average FCF yield of 2.33% , the current FCF yield is about 92.59% lower.
P/B
Median3y
12.56
Median5y
8.88
FCF Yield
Median3y
0.10
Median5y
2.33
Competitors Valuation Multiple
AI Analysis for PHAR
The average P/S ratio for PHAR competitors is 17.56, providing a benchmark for relative valuation. Pharming Group NV Corp (PHAR.O) exhibits a P/S ratio of 3.03, which is -82.75% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PHAR
1Y
3Y
5Y
Market capitalization of PHAR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PHAR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PHAR currently overvalued or undervalued?
Pharming Group NV (PHAR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.03 is considered Undervalued compared with the five-year average of -53.58. The fair price of Pharming Group NV (PHAR) is between 33.94 to 39.84 according to relative valuation methord. Compared to the current price of 17.89 USD , Pharming Group NV is Undervalued By 47.30% .
What is Pharming Group NV (PHAR) fair value?
PHAR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Pharming Group NV (PHAR) is between 33.94 to 39.84 according to relative valuation methord.
How does PHAR's valuation metrics compare to the industry average?
The average P/S ratio for PHAR's competitors is 17.56, providing a benchmark for relative valuation. Pharming Group NV Corp (PHAR) exhibits a P/S ratio of 3.03, which is -82.75% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Pharming Group NV (PHAR) as of Jan 09 2026?
As of Jan 09 2026, Pharming Group NV (PHAR) has a P/B ratio of 32.53. This indicates that the market values PHAR at 32.53 times its book value.
What is the current FCF Yield for Pharming Group NV (PHAR) as of Jan 09 2026?
As of Jan 09 2026, Pharming Group NV (PHAR) has a FCF Yield of 4.49%. This means that for every dollar of Pharming Group NV’s market capitalization, the company generates 4.49 cents in free cash flow.
What is the current Forward P/E ratio for Pharming Group NV (PHAR) as of Jan 09 2026?
As of Jan 09 2026, Pharming Group NV (PHAR) has a Forward P/E ratio of 337.40. This means the market is willing to pay $337.40 for every dollar of Pharming Group NV’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Pharming Group NV (PHAR) as of Jan 09 2026?
As of Jan 09 2026, Pharming Group NV (PHAR) has a Forward P/S ratio of 3.03. This means the market is valuing PHAR at $3.03 for every dollar of expected revenue over the next 12 months.